Elite in Anhidrosis

Atsushi Fukunaga

Takatsuki, JP 
Elite in Anhidrosis
Takatsuki, JP 
OverviewLocationsClinical Research

Overview

Atsushi Fukunaga practices in Takatsuki, Japan. Mr. Fukunaga is rated as an Elite expert by MediFind in the treatment of Anhidrosis. His top areas of expertise are Hives, Anhidrosis, Chronic Spontaneous Urticaria (CSU), Liver Embolization, and Cardiac Ablation.

His clinical research consists of co-authoring 162 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Anhidrosis.

Gender
Male

Locations

Takatsuki, Japan
Other Locations
Osaka, Japan
Fukuoka, Japan
Kobe, Japan
Nanakuma, 8140180, Japan
Fussa, Japan
Jonan, 8140180, Japan
Japan
Minato, 1088639, Japan
Tachikawa, 1908531, Japan
Chuo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema
A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

162 Total Publications

Thioredoxin Improves Contact Dermatitis through an Anti-inflammatory Mechanism Different from Glucocorticoids.
Thioredoxin Improves Contact Dermatitis through an Anti-inflammatory Mechanism Different from Glucocorticoids.
Journal: Free radical research
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fukunaga's expertise for a condition
ConditionClose
View All 51 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile